279 related articles for article (PubMed ID: 10994741)
1. Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.
Koral KF; Dewaraja Y; Li J; Barrett CL; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
J Nucl Med; 2000 Sep; 41(9):1579-86. PubMed ID: 10994741
[TBL] [Abstract][Full Text] [Related]
2. Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.
Koral KF; Dewaraja Y; Li J; Lin Q; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
J Nucl Med; 2003 Mar; 44(3):457-64. PubMed ID: 12621015
[TBL] [Abstract][Full Text] [Related]
3. CT-SPECT fusion plus conjugate views for determining dosimetry in iodine-131-monoclonal antibody therapy of lymphoma patients.
Koral KF; Zasadny KR; Kessler ML; Luo JQ; Buchbinder SF; Kaminski MS; Francis I; Wahl RL
J Nucl Med; 1994 Oct; 35(10):1714-20. PubMed ID: 7931676
[TBL] [Abstract][Full Text] [Related]
4. I-131 anti-B1 therapy/tracer uptake ratio using a new procedure for fusion of tracer images to computed tomography images.
Koral KF; Li J; Dewaraja Y; Barrett CL; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3004s-3009s. PubMed ID: 10541335
[TBL] [Abstract][Full Text] [Related]
5. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
[TBL] [Abstract][Full Text] [Related]
6. Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. Conjugate views compared with a hybrid method.
Koral KF; Francis IR; Kroll S; Zasadny KR; Kaminski MS; Wahl RL
Cancer; 2002 Feb; 94(4 Suppl):1258-63. PubMed ID: 11877754
[TBL] [Abstract][Full Text] [Related]
7. Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report.
Koral KF; Dewaraja Y; Clarke LA; Li J; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
Cancer Biother Radiopharm; 2000 Aug; 15(4):347-55. PubMed ID: 11041019
[TBL] [Abstract][Full Text] [Related]
8. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation.
Dewaraja YK; Wilderman SJ; Ljungberg M; Koral KF; Zasadny K; Kaminiski MS
J Nucl Med; 2005 May; 46(5):840-9. PubMed ID: 15872359
[TBL] [Abstract][Full Text] [Related]
9. Preliminary results from intensity-based CT-SPECT fusion in I-131 anti-B1 monoclonal-antibody therapy of lymphoma.
Koral KF; Lin S; Fessler JA; Kaminski MS; Wahl RL
Cancer; 1997 Dec; 80(12 Suppl):2538-44. PubMed ID: 9406707
[TBL] [Abstract][Full Text] [Related]
10. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in (131)I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma.
Boucek JA; Turner JH
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):458-69. PubMed ID: 15821965
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.
Blakkisrud J; Løndalen A; Martinsen AC; Dahle J; Holtedahl JE; Bach-Gansmo T; Holte H; Kolstad A; Stokke C
J Nucl Med; 2017 Jan; 58(1):48-54. PubMed ID: 27493270
[TBL] [Abstract][Full Text] [Related]
13. Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.
Dewaraja YK; Schipper MJ; Shen J; Smith LB; Murgic J; Savas H; Youssef E; Regan D; Wilderman SJ; Roberson PL; Kaminski MS; Avram AM
J Nucl Med; 2014 Jul; 55(7):1047-53. PubMed ID: 24842891
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
[TBL] [Abstract][Full Text] [Related]
15. Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood.
Boucek JA; Turner JH
Cancer Biother Radiopharm; 2014 Feb; 29(1):18-25. PubMed ID: 24134141
[TBL] [Abstract][Full Text] [Related]
16. Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma.
Assié K; Dieudonné A; Gardin I; Buvat I; Tilly H; Vera P
Cancer Biother Radiopharm; 2008 Feb; 23(1):53-64. PubMed ID: 18298329
[TBL] [Abstract][Full Text] [Related]
17. Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate.
Blakkisrud J; Løndalen A; Dahle J; Turner S; Holte H; Kolstad A; Stokke C
J Nucl Med; 2017 Jan; 58(1):55-61. PubMed ID: 27587710
[TBL] [Abstract][Full Text] [Related]
18. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
DeNardo GL; DeNardo SJ; O'Donnell RT; Kroger LA; Kukis DL; Meares CF; Goldstein DS; Shen S
Clin Lymphoma; 2000 Sep; 1(2):118-26. PubMed ID: 11707820
[TBL] [Abstract][Full Text] [Related]
19. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
[TBL] [Abstract][Full Text] [Related]
20. Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study.
Dewaraja YK; Wilderman SJ; Koral KF; Kaminski MS; Avram AM
Cancer Biother Radiopharm; 2009 Aug; 24(4):417-26. PubMed ID: 19694576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
